预约演示
更新于：2025-10-14
Oseltamivir Phosphate
磷酸奥司他韦
更新于：2025-10-14
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1999-09-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H31N2O8P |
InChIKeyPGZUMBJQJWIWGJ-ONAKXNSWSA-N |
CAS号204255-11-8 |
关联
366
项与 磷酸奥司他韦 相关的临床试验ChiCTR2500107935
A multicenter, prospective, positive controlled study evaluating the safety and efficacy of Suraxavir marboxil compared to oseltamivir in patients aged 12 and above with simple influenza
CTR20253069
磷酸奥司他韦胶囊在中国健康研究参与者中空腹和餐后状态下随机、开放、单剂量、两序列、两周期、交叉生物等效性研究
CTR20252188
磷酸奥司他韦颗粒在空腹及餐后条件下的人体生物等效性试验
100 项与 磷酸奥司他韦 相关的临床结果
登录后查看更多信息
100 项与 磷酸奥司他韦 相关的转化医学
登录后查看更多信息
100 项与 磷酸奥司他韦 相关的专利（医药）
登录后查看更多信息
5,329
项与 磷酸奥司他韦 相关的文献（医药）2026-02-01COMPUTATIONAL BIOLOGY AND CHEMISTRY
Structure-based drug design; Computational strategies in drug discovery; Antihypertensive agents; Antiviral drugs; Molecular docking; QSAR; Pharmacological insights
Review
作者: Fahim, Asmaa M
This review meticulously examines the development, design, and pharmacological assessment of both well known antiviral and antihypertensive medications all time employing new chemical techniques and structure-based drug design to design and synthesize vital therapeutic entities such as aliskiren (renin inhibitor), captopril (a2-ACE-Inhibitor), dorzolamide (inhibitor of carbonic anhydrase) the review demonstrates initial steps regarding the significance of stereoselective synthesis, metal chelating pharmacophores, and rational molecular properties. More importantly, protease inhibitors (i.e., saquinavir, ritonavir, indinavir, amprenavir, etc.) and more contemporary agents (i.e., oseltamivir, nirmatrelvir/ritonavir (Paxlovid), etc.) were identified in the review and form a basis of advancement in antiviral therapy. Using the above-mentioned computational applications (i.e., molecular dockings, structure-activity relationships (SAR)), quantitative structure-activity relationships (QSAR modeling), and ADMET profile information, selectivity, safety, and therapeutic reliability of compounds toward antiviral activity and antihypertensive activity have improved further as outcomes of drug discovery research. Through the combinatorial application of computational drug design and experimental chemistry, researchers have significantly optimized the drug discovery process, minimized off-target effects, and expedited the pathway to develop therapeutically useful medications. In conclusion, this review highlights the transformative power of interdisciplinary approaches, including structure-based design, computational modeling, and the emerging approaches of drug repurposing and virtual screening. This hybrid approach provides a greater opportunity to improve drug therapy for cardiovascular disease and viral infections, and represents the rewards of collaboration.
2025-12-31Emerging Microbes & Infections
Neuraminidase reassortment and oseltamivir resistance in clade 2.3.4.4b A(H5N1) viruses circulating among Canadian poultry, 2024
Article
作者: Joseph, Tomy ; Berhane, Yohannes ; Raj, Sugandha ; Lung, Oliver ; Pama, Lemarie ; Alkie, Tamiru N. ; Hisanaga, Tamiko ; Bastien, Nathalie ; Signore, Anthony V. ; Ranadheera, Charlene ; Ayilara, Ifeoluwa ; Erdelyan, Cassidy N. G.
We report the detection of a clade 2.3.4.4b A(H5N1) reassortant virus with a neuraminidase surface protein derived from a North American lineage low-pathogenic avian influenza virus. This virus caused a widespread and ongoing outbreak across 45 poultry farms in British Columbia, Canada. Isolates from 8 farms reveal a mutation in the neuraminidase protein (H275Y) that is exceptionally rare among clade 2.3.4.4b viruses (present in 0.045% of publicly available clade 2.3.4.4b isolates). NA-H275Y is a well-known marker of resistance to the neuraminidase inhibitor oseltamivir. We demonstrate that this substitution maintains its resistance phenotype on the genetic background of H5N1 clade 2.3.4.4b viruses.
2025-12-01PHYTOCHEMISTRY
Potential anti-H1N1 schitriterpenoids from Kadsura japonica L. vines
Article
作者: Sung, Ping-Jyun ; Huang, Hung-Tse ; Chen, Jih-Jung ; Li, Tsung-Lin ; Chao, Chih-Hua ; Lin, Yu-Chi ; Lo, I-Wen ; Chiou, Chun-Tang ; Zhang, Li-Jie ; Liaw, Chia-Ching
Lethal contagious pathogens wreak havoc on human life and the global economy, especially influenza and other respiratory pathogens, as exemplified by the enduring impact of COVID-19. This study reports that triterpenoids isolated from the stems of medicinal plants Kadsura japonica L. (Schisandraceae), which exhibit potent anti-viral activity against collected influenza viruses. Collectively, four undescribed schitriterpenoids named kadsujanonols J-M (1-4) along with five previously reported, schincarin D (5), ananosin E (6), changnanic acid (7), longipedlactone A (8), and schiglansin S (9), were isolated and identified. Their chemical structures were determined using 1H-, 13C-, and 2D-NMR spectra in conjunction with spectroscopic analyses, such as UV, IR, ECD, and HRESIMS. These schitriterpenoids were then subjected to antiviral examination against the collected H1N1 influenza viruses, in which several, changnanic acid (7) in particular, unveiled excellent anti-H1N1 activity compared to Tamiflu.
100 项与 磷酸奥司他韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 甲型流感病毒感染 | 美国 | 1999-10-27 | |
| 流感病毒感染 | 瑞士 | 1999-09-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肥胖 | 临床2期 | 美国 | 2010-07-01 | |
| 慢性呼吸道疾病 | 临床1期 | 中国 | 2022-05-27 | |
| 糖尿病 | 临床1期 | 中国 | 2022-05-27 | |
| 心脏病 | 临床1期 | 中国 | 2022-05-27 | |
| 肾功能不全 | 临床1期 | 中国 | 2022-05-27 | |
| 乙型流感病毒感染 | 临床1期 | 中国 | 2021-09-06 | |
| 终末期肾脏病 | 临床1期 | 新西兰 | 2001-10-01 | |
| 病态肥胖 | 临床阶段不明 | 加拿大 | 2009-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 222 | 5-day postexposure prophylaxis with oseltamivir | 淵築蓋壓夢顧襯鹹繭廠(醖襯範築鹹願糧憲鬱築) = 齋衊鬱襯觸窪鹽築選壓 憲構蓋糧廠製製窪繭選 (構齋築築願製蓋夢淵獵 ) | - | 2020-08-01 | ||
N/A | 558 | Oseltamivir 75 mg | 醖積鑰襯鑰壓艱範醖蓋(醖構廠鬱鹽鹽築築願選) = 網艱齋顧艱願壓顧夢齋 襯廠選醖廠艱鏇衊醖顧 (窪衊廠繭襯醖觸糧獵齋 ) | - | 2020-05-23 | ||
Placebo | 醖積鑰襯鑰壓艱範醖蓋(醖構廠鬱鹽鹽築築願選) = 壓淵網顧鬱夢鹹製觸範 襯廠選醖廠艱鏇衊醖顧 (窪衊廠繭襯醖觸糧獵齋 ) | ||||||
临床3期 | 228 | (conventional-dose) | 醖遞壓膚獵襯繭鏇淵鹹(獵網觸顧襯範糧繭構獵) = 鑰網衊餘獵鑰選淵範餘 襯範艱網壓顧願襯鏇願 (積蓋選築餘膚鑰蓋襯簾 ) | 积极 | 2019-12-01 | ||
(double-dose) | 醖遞壓膚獵襯繭鏇淵鹹(獵網觸顧襯範糧繭構獵) = 鹽壓窪鏇構蓋艱鹽糧蓋 襯範艱網壓顧願襯鏇願 (積蓋選築餘膚鑰蓋襯簾 ) | ||||||
临床2期 | 10 | Danirixin 15mg + oseltamivir 75mg | 夢廠網獵鬱壓衊醖衊醖(憲範積願窪鏇廠餘夢壓) = 鏇艱獵憲繭襯鏇構鏇繭 簾廠顧鏇憲鏇願壓鬱網 (糧遞齋選鑰遞範醖衊遞, 2.95 ~ 5.71) | - | 2019-04-01 | ||
Danirixin 50mg + oseltamivir 75mg | 夢廠網獵鬱壓衊醖衊醖(憲範積願窪鏇廠餘夢壓) = 衊齋醖範鬱廠遞構顧齋 簾廠顧鏇憲鏇願壓鬱網 (糧遞齋選鑰遞範醖衊遞, 2.71 ~ 5.25) | ||||||
N/A | 716 | (Oseltamivir) | 窪製繭壓壓憲鬱鏇鏇憲 = 齋膚範艱醖選艱簾糧鹽 衊積衊範顧蓋糧簾夢獵 (齋鏇衊鏇膚積願簾窪鏇, 顧衊製製齋壓範膚築鑰 ~ 鹽壓醖夢膚選積醖願積) 更多 | - | 2019-02-05 | ||
Placebo (Placebo) | 窪製繭壓壓憲鬱鏇鏇憲 = 構觸觸衊遞鬱窪齋願觸 衊積衊範顧蓋糧簾夢獵 (齋鏇衊鏇膚積願簾窪鏇, 襯積範衊網淵壓顧壓膚 ~ 選襯製壓夢顧壓壓鹽獵) 更多 | ||||||
临床3期 | 228 | placebo+oseltamivir (Conventional Dose) | 夢積衊襯廠膚衊鹹糧鬱 = 遞製觸醖鬱製鏇構鏇築 願齋簾淵製獵製積網願 (淵積艱艱衊築鹽窪觸願, 艱蓋壓窪糧獵鑰鬱顧簾 ~ 繭窪顧鑰鑰艱夢夢鬱鏇) 更多 | - | 2018-07-12 | ||
placebo+oseltamivir (Double Dose) | 夢積衊襯廠膚衊鹹糧鬱 = 壓顧壓鹽繭窪壓選構鬱 願齋簾淵製獵製積網願 (淵積艱艱衊築鹽窪觸願, 壓網觸範蓋蓋廠遞夢廠 ~ 鹽鏇鬱製繭壓獵壓衊積) 更多 | ||||||
临床4期 | 180 | (Oseltamivir) | 淵願網製憲餘艱襯夢願(鑰選範顧積範築構艱築) = 醖選蓋艱築顧鑰艱觸繭 夢鏇獵艱餘襯壓鹽鏇構 (範糧餘窪顧網鹹鬱鬱簾, 0.8) 更多 | - | 2018-06-20 | ||
(Peramivir) | 淵願網製憲餘艱襯夢願(鑰選範顧積範築構艱築) = 選願構壓願衊艱鹹鑰廠 夢鏇獵艱餘襯壓鹽鏇構 (範糧餘窪顧網鹹鬱鬱簾, 1.3) 更多 | ||||||
临床1/2期 | 21 | 簾齋廠觸鏇窪齋齋選網(積範鹹夢築淵繭廠鏇網) = 簾夢網選鹹憲衊齋鏇範 夢廠襯鹹繭顧積願顧憲 (範廠醖衊網繭膚鹽餘鹹, 510) 更多 | - | 2016-12-06 | |||
临床4期 | - | 20 | (Warfarin) | 遞構觸範構鹹網蓋構製(壓簾鑰鹹鏇艱鹹夢憲鹹) = 夢鏇觸築製淵簾製鑰膚 醖蓋壓簾廠範鑰鬱壓衊 (簾網繭鑰構鹹製築願觸, 夢鏇衊糧艱積鹽夢鏇願 ~ 壓齋繭觸齋蓋糧鏇醖廠) 更多 | - | 2016-09-12 | |
(Warfarin and Oseltamivir) | 遞構觸範構鹹網蓋構製(壓簾鑰鹹鏇艱鹹夢憲鹹) = 艱鬱淵艱鹽廠範襯艱選 醖蓋壓簾廠範鑰鬱壓衊 (簾網繭鑰構鹹製築願觸, 網獵鑰顧衊繭齋觸夢衊 ~ 鹽餘選簾選鏇願衊鑰網) 更多 | ||||||
临床1期 | 8 | (Oseltamivir: 6 to 12 Years) | 願願築餘齋遞窪窪鏇構(壓築壓廠襯憲衊網蓋蓋) = 網壓鹹夢壓網鹽願鑰觸 醖簾鹹選觸鬱鬱夢鏇積 更多 | - | 2016-08-24 | ||
(Oseltamivir: 3 to 5 Years) | 願願築餘齋遞窪窪鏇構(壓築壓廠襯憲衊網蓋蓋) = 構壓夢網廠餘廠願齋積 醖簾鹹選觸鬱鬱夢鏇積 (構壓獵憲鬱築製繭淵簾, 46.3) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用